₹89.03
▲ +1.16 +1.32%
As of 05 Aug 2026 · delayed
NSE Listed · Healthcare
Bal Pharma Limited (BALPHARMA)
20-day avg volume: 66K shares
- High debt relative to equity.
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹74 Cr | ₹74 Cr | ₹73 Cr | ₹82 Cr | ₹66 Cr | ₹74 Cr | ₹88 Cr | ₹84 Cr |
| EBITDA | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹7 Cr | ₹4 Cr | ₹5 Cr | ₹7 Cr | ₹7 Cr |
| Net Profit | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹5 Cr | ₹0 Cr | ₹1 Cr | ₹2 Cr | ₹4 Cr |
| EPS | — | — | — | — | — | — | — | — |
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹75 Cr | ₹73 Cr | ₹82 Cr | ₹305 Cr | ₹66 Cr | ₹74 Cr | ₹87 Cr | ₹84 Cr |
| EBITDA | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹22 Cr | ₹4 Cr | ₹5 Cr | ₹7 Cr | ₹7 Cr |
| Net Profit | ₹1 Cr | ₹1 Cr | ₹6 Cr | ₹7 Cr | ₹0 Cr | ₹1 Cr | ₹2 Cr | ₹4 Cr |
| EPS | — | — | — | 4.54 | — | — | — | — |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹260 Cr | ₹261 Cr | ₹238 Cr | ₹240 Cr | ₹261 Cr | ₹313 Cr | ₹320 Cr | ₹336 Cr |
| Total Liabilities | ₹200 Cr | ₹201 Cr | ₹193 Cr | ₹187 Cr | ₹202 Cr | ₹249 Cr | ₹248 Cr | ₹258 Cr |
| Equity | ₹60 Cr | ₹60 Cr | ₹45 Cr | ₹53 Cr | ₹58 Cr | ₹64 Cr | ₹72 Cr | ₹77 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹2 Cr | ₹10 Cr | ₹23 Cr | ₹22 Cr | ₹28 Cr | ₹-1 Cr | ₹27 Cr | ₹22 Cr |
| Investing | ₹-4 Cr | ₹-8 Cr | ₹-5 Cr | ₹-6 Cr | ₹-9 Cr | ₹-22 Cr | ₹-19 Cr | ₹-15 Cr |
| Financing | ₹4 Cr | ₹0 Cr | ₹-20 Cr | ₹-17 Cr | ₹-17 Cr | ₹24 Cr | ₹-1 Cr | ₹-8 Cr |
| Free Cash Flow | ₹2 Cr | ₹10 Cr | ₹23 Cr | ₹22 Cr | ₹28 Cr | ₹-1 Cr | ₹27 Cr | ₹22 Cr |
Healthcare · Drug Manufacturers - Specialty & Generic
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.
www.balpharma.com ↗As of 2026-06-30
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 51.6% | 51.2% | 51.2% | 51.2% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% |
| FIIs | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 48.3% | 48.6% | 48.6% | 48.6% | 49% | 49% | 49% | 49% | 48.9% | 49% | 49% | 49% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 15,529 | 15,060 | 14,772 | 15,014 | 16,007 | 15,667 | 15,723 | 15,826 | 15,774 | 15,520 | 15,214 | 14,974 |
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
| Name | Category | Stake | Shares |
|---|---|---|---|
| Shailesh Siroya | Shareholding of Promoter and Promoter Group | 17.2% | 27,45,459 |
| Micro Labs Limited | Shareholding of Promoter and Promoter Group | 12.6% | 20,11,736 |
| Anita Siroya | Shareholding of Promoter and Promoter Group | 6.6% | 10,49,220 |
| Prakash Chandra Jain | Public Shareholding | 3.4% | 5,48,311 |
| Ram Keshav Murthy | Public Shareholding | 3.3% | 5,27,600 |
| Anand Surana | Shareholding of Promoter and Promoter Group | 3.3% | 5,25,686 |
| Chandraprakash Dheerajmal Siroya | Shareholding of Promoter and Promoter Group | 3.1% | 4,86,420 |
| Dilip Surana | Shareholding of Promoter and Promoter Group | 3% | 4,74,994 |
| Naresh D P | Public Shareholding | 1.9% | 3,00,000 |
| Shreya Mardia | Public Shareholding | 1.9% | 3,00,000 |
| Asha Tapidas Dodhia | Public Shareholding | 1.8% | 2,93,247 |
| Archana Surana | Shareholding of Promoter and Promoter Group | 1.8% | 2,84,996 |
| Gautam Chand Mehta | Public Shareholding | 1.2% | 1,84,966 |
| Monica Surana | Shareholding of Promoter and Promoter Group | 1.1% | 1,79,909 |
| Dilip Surana (huf) | Shareholding of Promoter and Promoter Group | 1.1% | 1,69,995 |
| Anita Chandraprakash Siroya | Shareholding of Promoter and Promoter Group | 0.8% | 1,22,687 |
| Jivi Dheerajmal Siroya | Shareholding of Promoter and Promoter Group | 0.3% | 46,080 |
| Shrenik Siroya | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Name | Designation | Year |
|---|---|---|
| Shailesh Siroya | ED / MD / Promoter | 2025 |
| Himesh Virupakshaya | E D & Wholetime Director | 2025 |
| H S Venkatesh | Independent Non Exe. Director | 2025 |
| Nicola Neeladri | Independent Non Exe. Director | 2025 |
| Jatish Sheth | Independent Non Exe. Director | 2025 |
| Ravindrakumar Kothari | Independent Non Exe. Director | 2025 |
| Abdul Basith | Company Sec. & Compli. Officer | 2025 |
| Bheekamchand Mukesh | Additional Director | 2025 |
| Segment | Revenue | Share |
|---|---|---|
| manufacturing and marketing of phar | ₹0 Cr | — |
| Region | Revenue | Share |
|---|---|---|
| India | ₹105 Cr | 46.5% |
| Other than India | ₹121 Cr | 53.5% |
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 25 | 16 | 16 |
| Type | Date | Value | Remark |
|---|---|---|---|
| dividend | 2025-09-18 | ₹1.2 (12%) | Final |
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 1 | 0 | 0 | 3 | 4 | 8 |
| 2025 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 3 | 1 | 4 |
5 recent disclosure(s)
3 disclosure(s)
📍 21 & 22 Bommasandra Indl Area, Hosur Road, Bangalore, Karnataka, 560092
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search
